An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes

References

• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 2004;21:657-65
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Glycemic variability: it's not just about A1C anymore!. Diabetes Tech Therapeut 2005;75:780-3
   Google Scholar
• National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update). Available at: http://www.nice.org.uk/Guidance/CG66 [Last accessed 17 November 2008]
   Google Scholar
• Deiss D, Kordonouri O, Hartmann R, et al. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes. Pediatr Diabetes 2007;8:157-62
   PubMed Web of Science ®Google Scholar
• Abrahamian H, Francesconi M, Loiskandl A, et al. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring. Diabetes Tech Therapeut 2004;6:31-7
   PubMedGoogle Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Selvin E, Coresh J, Golden SH, et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005;165:1910-16
   PubMed Web of Science ®Google Scholar
• Jenny-Avital ER, Luan FL, Nguyen K, et al. Intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1519-21
   PubMedGoogle Scholar
• ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
   Google Scholar
• The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: Eur Heart J 2007;28:88-136
   Google Scholar
• Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-3
   PubMed Web of Science ®Google Scholar
• Duckworth WC, McCarren M, Abraira C; VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocr Pract 2006;12(Suppl. 1):85-8
   Google Scholar
• Ceriello A. Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J 2004;147:803-7
   PubMed Web of Science ®Google Scholar
• Slama G. Clinical significance of post-prandial blood glucose excursions in type 1 and type 2 diabetes mellitus. Int J Clin Pract 2000;112(Suppl.):9-12
   Google Scholar
• Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c-Derived Average Glucose (ADAG) Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-8
   Google Scholar
• Mastrototaro JJ. The MiniMed continuous glucose monitoring system. Diabetes Tech Therapeut 2000;2(Suppl. 1):S13-8
   PubMedGoogle Scholar
• Rebrin K, Steil GM, van Antwerp WP, et al. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am J Physiol 1999;277(3 Pt 1):E561-71
   PubMed Web of Science ®Google Scholar
• Boyne MS, Silver DM, Kaplan J, et al. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 2003;52:2790-4
   PubMed Web of Science ®Google Scholar
• Metzger M, Leibowitz G, Wainstein J, et al. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 2002;25:1185-91
   PubMed Web of Science ®Google Scholar
• Steil GM, Rebrin K, Mastrototaro J, et al. Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor. Diabetes Tech Therapeut 2003;5:27-31
   PubMedGoogle Scholar
• Guerci B, Floriot M, Böhme P, et al. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care 2003;26:582-9
   PubMed Web of Science ®Google Scholar
• Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabet Med 2003;20:1012-15
   PubMed Web of Science ®Google Scholar
• Djakoure-Platonoff C, Radermecker R, Reach G, et al. Accuracy of the continuous glucose sensor. Diabetes Care 2002;25:1185-91
   PubMed Web of Science ®Google Scholar
• McGowan K, Thomas W, Moran A. Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 1 diabetes. Diabetes Care 2002;25:1499-503
   PubMed Web of Science ®Google Scholar
• Cheyne E, Kerr D. Making ‘sense’ of diabetes: using a continuous glucose sensor in clinical practice. Diabetes Metabol Res Rev 2002;18(Suppl. 1):S43-S48
   PubMedGoogle Scholar
• Clarke WL. The original Clarke Error Grid Analysis (EGA). Diabetes Tech Therapeut 2005;7:776-9
   PubMedGoogle Scholar
• Lagarde WH, Barrows FP, Davenport ML, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trial. Pediatr Diabetes 2006;7:159-64
   PubMed Web of Science ®Google Scholar
• Deiss D, Hartmann R, Schmidt J, et al. Results of a randomised controlled cross-over trial on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycaemic control in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2006;11:63-7
   Google Scholar
• Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 2003;111:933-8
   PubMed Web of Science ®Google Scholar
• Yates K, Hasnat Milton A, Dear K, et al. Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens: a randomized controlled trial. Diabetes Care 2006;29:1512-17
   PubMed Web of Science ®Google Scholar
• Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008;25:924-32
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005;22:749-55
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CLl, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:523-34
   Google Scholar
• Chase HP, Kim LM, Owen SL, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2001;107:222-6
   PubMed Web of Science ®Google Scholar
• Tanenberg R, Bode B, Lane W, et al. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc 2004;79:1521-6
   PubMed Web of Science ®Google Scholar
• Chico A, Vidal-Ríos P, Subirà M, et al. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003;26:1153-7
   PubMed Web of Science ®Google Scholar
• Chetty VT, Almulla A, Odueyungbo A, et al. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in Type I diabetic patients: a systematic review. Diab Res Clin Pract 2008;81:79-87
   PubMed Web of Science ®Google Scholar
• Golicki DT, Golicka D, Groele L, et al. Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetologia 2008;51:233-40
   PubMed Web of Science ®Google Scholar
• Reach G. Continuous glucose monitoring and diabetes health outcomes: a critical appraisal. Diabetes Tech Therapeut 2008;10:69-80
   PubMed Web of Science ®Google Scholar
• Boland E, Monsod T, Delucia M, et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24:1858-62
   PubMed Web of Science ®Google Scholar
• Schiaffini R, Ciampalini P, Fierabracci A, et al. The Continuous Glucose Monitoring System (CGMS) in type 1 diabetic children is the way to reduce hypoglycemic risk. Diabetes Metabol Res Rev 2002;18:324-9
   PubMed Web of Science ®Google Scholar
• Amin R, Ross K, Acerini CL, et al. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: using of continuous glucose monitoring system. Diabetes Care 2003;26:662-7
   PubMed Web of Science ®Google Scholar
• Gandrud LM, Xing DY, Kollman C, et al. The medtronic MiniMed gold continuous glucose monitoring system: an effective means to discover hypo- and hyperglycemia in children under 7 years of age. Diabetes Tech Therapeut 2007;9:307-16
   PubMed Web of Science ®Google Scholar
• Wiltshire EJ, Newton K, McTavish L. Unrecognised hypoglycaemia in children and adolescents with type 1 diabetes using the continuous glucose monitoring system: prevalence and contributors. J Paediatr Child Health 2006;42:758-63
   PubMed Web of Science ®Google Scholar
• Yogev Y, Chen R, Ben-Haroush A, et al. Continuous glucose monitoring for the evaluation of gravid women with type 1 diabetes mellitus. Obstet Gynecol 2003;101:633-8
   PubMed Web of Science ®Google Scholar
• Desouza C, Salazar H, Cheong B, et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26:1485-9
   PubMed Web of Science ®Google Scholar
• Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Tech Therapeut 2003;5:19-26
   PubMedGoogle Scholar
• Parati G. Continuous finger monitoring of blood pressure: advantages, problems and perspectives. Blood Press Monit 2000;5:47-9
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl. 1):5-26
   PubMed Web of Science ®Google Scholar
• Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26(4):1176-80
   PubMed Web of Science ®Google Scholar
• McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl. 1):S7-S19
   PubMedGoogle Scholar
• McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl. 1):S21-S31
   Google Scholar
• National Institute for Clinical Excellence. The guidelines manual. Appendix H: Methodology checklist: economic evaluations. Available at: http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/GuidelinesManual2009.jsp [Last accessed 1st July 2009]
   Google Scholar
• Warren E, Weatherly Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8(45).
   Web of Science ®Google Scholar
• NICE Guidance, Diabetes – insulin pump therapy. Available at: http://www.nice.org.uk/Guidance/TA151 [Last accessed 19 March 2009]
   Google Scholar
• Henriksen OM, Røder ME, Prahl JB, et al. Diabetic ketoacidosis in Denmark incidence and mortality estimated from public health registries. Diabetes Res Clin Pract 2007;76:51-6
   PubMed Web of Science ®Google Scholar